Darren A. DeWalt, MD, MPH

Articles by Darren A. DeWalt, MD, MPH

Impact of Including Drug Spending in Oncology Alternative Payment Models

ByLuca Maini, PhD,Jacob P. Klimek, PhD,David C. Johnson, MD, MPH,George M. Holmes, PhD,Darren A. DeWalt, MD, MPH

November 3rd 2023

This study demonstrates a method for understanding the effects of drug spending in the design of alternative payment models.

Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management

ByRichard O. White, MD,Darren A. DeWalt, MD, MPH,Robert M. Malone, PharmD,Chandra Y. Osborn, PhD, MPH,Michael P. Pignone, MD, MPH,Russell L. Rothman, MD, MPP

January 14th 2010

A subanalysis of a successful algorithm-driven primary care–based diabetes disease management program examines the relationships among patient characteristics, labor inputs, and improvement in A1C level.

Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program

ByRussell L. Rothman, MD, MPP,Stephanie A. So, PhD,John Shin, BS,Robert M. Malone, PharmD,Betsy Bryant, PharmD,Darren A. DeWalt, MD, MPH,Michael P. Pignone, MD, MPH,Robert S. Dittus, MD, MPH

May 1st 2006

Latest Updated Articles

Impact of Including Drug Spending in Oncology Alternative Payment Models
Published: November 3rd 2023 | Updated:
Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program
Published: May 1st 2006 | Updated:
Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management
Published: January 14th 2010 | Updated:

Darren A. DeWalt, MD, MPH

Articles by Darren A. DeWalt, MD, MPH

Impact of Including Drug Spending in Oncology Alternative Payment Models

Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management

Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program

Latest Updated Articles

Trending on AJMC

2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells

FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years

Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD

Pricing and Insurance Networks in Outpatient Surgery Markets

Mediterranean Diet Improves Psoriasis Severity, Study Finds